Venus Remedies expands globally with Elores launch in Ecuador: Tackling multi-drug-resistant infections

Venus Remedies Limited, renowned for healthcare innovation, continues its global growth trajectory with the latest launch of its cutting-edge antibiotic formulation, Elores, in Ecuador. Building on previous successful launches in countries including India, Saudi Arabia, and Tanzania, this expansion further cements the company’s commitment to tackling antibiotic resistance on a global scale.

Elores stands out as a novel patented Antibiotic Adjuvant Entity, designed to combat multi-drug-resistant infections. Comprising a beta-lactam antibiotic, a beta-lactamase inhibitor, and an Antibiotic Resistance Breaker (ARB), Elores synergistically boosts antibiotic activity, suppressing resistance emergence. This revolutionary product promises to improve healthcare quality in Ecuador, given its efficacy against diverse bacterial strains.

Saransh Chaudhary, CEO of Venus Medicine Research Centre, elaborated on the innovation behind Elores. “Through dedicated R&D spanning over a decade, we’ve sought solutions to antibiotic resistance. Elores, as a trusted carbapenem saver, emerged from extensive studies on ARBs. Witnessing its positive impact on patients has been immensely rewarding,” he said.

Ecuador, the eighth-largest economy in Latin America, showcases a rising pharmaceutical market, valued at US$1.6 billion. With a compound annual growth rate (CAGR) of 5.5% from 2015 to 2020, and a heavy reliance on Indian antibiotic imports (totalling US$3.5 million in 2022 alone), Elores’s launch is set to influence not only Ecuador but potentially ripple into other crucial Latin American countries.

Alarming antibiotic resistance rates in Ecuador, reaching up to 85% for certain pathogens, underscores the pressing need for Elores. The broader Latin American region mirrors this dire situation, emphasizing the broader implications of antibiotic resistance and the consequential spread of infectious diseases.

Aditi K Chaudhary, President of International Business at Venus Remedies, expressed enthusiasm about the Ecuador launch. “Elores embodies our unwavering dedication to innovative solutions against antibiotic resistance. Our primary goal is to empower Ecuadorian healthcare professionals, enabling improved patient outcomes,” she commented.

Elores’s acclaim isn’t new; its synergistic antibiotic combination has been recognized for effectively battling challenging infections. This acknowledgment extends back to 2013 when Elores was crowned the best innovation, securing a gold medal at the India Innovation Growth Program.

This Ecuadorian expansion marks yet another milestone for Venus Remedies Limited, reaffirming their mission to confront the escalating global antibiotic resistance crisis. With products like Elores, the company strives to make tangible differences in global healthcare standards.